UBS Group’s Diebold Nixdorf Incorporated DBD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-75,800
Closed -$510K 11386
2022
Q1
$510K Buy
+75,800
New +$648K ﹤0.01% 4676
2019
Q2
Sell
-225,000
Closed -$2.49M 8267
2019
Q1
$2.49M Buy
+225,000
New +$1.57M ﹤0.01% 2808
2016
Q3
Sell
-17,500
Closed -$435K 8019
2016
Q2
$435K Hold
17,500
﹤0.01% 3998
2016
Q1
$506K Buy
+17,500
New +$457K ﹤0.01% 3770
2015
Q3
Sell
-1,900
Closed -$67K 8722
2015
Q2
$67K Sell
1,900
-100
-5% -$3.53K ﹤0.01% 5745
2015
Q1
$71K Buy
2,000
+1,400
+233% +$47.2K ﹤0.01% 5720
2014
Q4
$21K Buy
+600
New +$21.2K ﹤0.01% 7619

Other funds holding DBD

UBS Group's DBD Position: Q2 2023 in Review

UBS Group sold out of Diebold Nixdorf Incorporated (DBD) in Q2 2023, closing a stake of 280,745 shares — an estimated $337K sold.

UBS Group first reported a position in DBD in Q4 2014 and held it in 34 quarters. The position peaked at $6.27M in Q1 2018. 7 funds tracked by Wall St. Rank hold DBD as of Q2 2023.

  • UBS Group reported no remaining Diebold Nixdorf Incorporated position as of Q2 2023 after selling out during the quarter.
  • UBS Group sold 280,745 Diebold Nixdorf Incorporated shares in Q2 2023, an estimated $337K.
  • UBS Group first reported a position in Diebold Nixdorf Incorporated in Q4 2014 and held it in 34 quarters.
  • UBS Group's Diebold Nixdorf Incorporated position peaked at $6.27M in Q1 2018.
  • 7 funds tracked by Wall St. Rank held Diebold Nixdorf Incorporated as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.